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Abstract
Withanolides are a large group of steroidal lactones found in Solanaceae plants that exhibit potential anticancer activities.
We have previously demonstrated that a withanolide, tubocapsenolide A, induced cycle arrest and apoptosis in human
breast cancer cells, which was associated with the inhibition of heat shock protein 90 (Hsp90). To investigate whether other
withanolides are also capable of inhibiting Hsp90 and to analyze the structure-activity relationships, nine withanolides with
different structural properties were tested in human breast cancer cells MDA-MB-231 and MCF-7 in the present study. Our
data show that the 2,3-unsaturated double bond-containing withanolides inhibited Hsp90 function, as evidenced by
selective depletion of Hsp90 client proteins and induction of Hsp70. The inhibitory effect of the withanolides on Hsp90
chaperone activity was further confirmed using in vivo heat shock luciferase activity recovery assays. Importantly, Hsp90
inhibition by the withanolides was correlated with their ability to induce cancer cell death. In addition, the withanolides
reduced constitutive NF-kB activation by depleting IkB kinase complex (IKK) through inhibition of Hsp90. In estrogen
receptor (ER)-positive MCF-7 cells, the withanolides also reduced the expression of ER, and this may be partly due to Hsp90
inhibition. Taken together, our results suggest that Hsp90 inhibition is a general feature of cytotoxic withanolides and plays
an important role in their anticancer activity.
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Introduction
Withanolides are a group of naturally occurring steroidal
lactones which are found in certain genera of the Solanaceae
family. Some withanolide-containing plants have been known as
folk remedies for centuries. For example, Withania somnifera
contains a major withanolide- withaferin A, has been traditionally
used in India for treatment of arthritis and other musculoskeletal
conditions, and as a general tonic [1]. Pharmacological studies
have revealed that besides anti-inflammatory activity, withanolides
possess immunoregulatory, anti-tumor, anti-angiogenic, anti-inva-
sive, and chemopreventive effects [2]. In addition, there are over
350 withanolides isolated and identified to date [3]; the diverse
structural analogs provide a great opportunity for the study of
structure-activity relationships, target identification, and lead
optimization. Therefore, withanolides represent promising lead
compounds for development of new anticancer drugs.
In our previous study, we have found that tubocapsenolide A, a
novel withanolide from a native Taiwanese plant Tubocapsicum
anomalum (Franchet and Savatier) Makino (Solanaceae), exhibited
significant cytotoxicity against a panel of cancer cell lines [4].
Further study on the mechanism of action revealed that
tubocapsenolide A inhibited the function of heat shock protein
90 (Hsp90) through thiol oxidation, and thus caused the depletion
of Hsp90 client proteins, including Akt, CDK4, cyclin D, and
mutant P53 [5]. Because Hsp90 client proteins play critical roles in
the regulation of cell proliferation, survival, and apoptosis, it is
suggested that tubocapsenolide A exerted its anticancer effect by
inhibiting Hsp90. Subsequent to our study, Yu et al. reported that
another withanolide withaferin A also has the same inhibitory
effect on Hsp90 [6]. More recently, by using molecular docking
approach, Grover et al. predicted that WA has the potential to
inhibit the association of Hsp90 to its co-chaperone Cdc37 by
disrupting the stability of attachment of Hsp90 to Cdc37 [7].
Therefore, we wondered whether the Hsp90-inhibitory effect is a
general characteristic of withanolides and contributes to their
anticancer effect. In the present study, we compared nine
withanolides with different structural features for their cytotoxicity
and Hsp90-inhibitory activity, and found a good correlation
between these two effects. In addition, structure activity analysis
revealed a critical requirement of the a, b-unsaturated ketone unit
in the ring A of withanolides for the inhibitory effect on Hsp90.
Materials and Methods
Materials
Tubocapsenolide A, tubocapsenolide B, tubocapsanolide C,
tubocapsanolide E, and anomanolide A were isolated from
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37764Tubocapsicum anomalum as described previously [4]. 4b-Hydroxy-
withanolide, withanolide E, and peruvianolide H were isolated
from Physalis peruviana [8]. Withaferin A was purchased from
ChromaDex (Irvine, CA). The purities of the withanolides used in
the study are over 98% determined by high pressure liquid
chromatography. The withanolides were dissolved in DMSO, and
the final concentration of DMSO in culture medium was 0.1%.
Anti-Poly(ADP-ribose)polymerase, anti-caspase-3, anti-Raf-1, an-
ti-CDK4 antibodies were from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA). Anti-Akt, anti-IKKa, anti-IKKb, anti-IkB,
anti-phospho-IkB, anti-NF-kB, and anti-phospho-NF-kB antibod-
ies were from Cell Signaling Technology (Beverly, MA). Anti-
Hsp90 and anti-Hsp70 antibodies were from Stressgen Biotech-
nologies (San Diego, CA). ONE-Glo
TM luciferase assay system was
purchased from Promega (Madison, WI). Geldanamycin, N-
acetylcysteine, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazoli-
um bromide (MTT), and all other chemicals were obtained from
Sigma Chemical Co (St Louis, MO).
Cell culture
MDA-MB-231 and MCF-7 human breast cancer cells were
obtained from American Tissue Culture Collection. Cells were
incubated at 37uC in a humidified atmosphere containing 5%
CO2 in RPMI 1640 medium, supplemented with 10% fetal bovine
serum, penicillin (100 IU/ml) and streptomycin (100 mg/ml). The
cells were harvested by trypsinization and plated 24 h before
treatment with the test drugs.
Evaluation of cell viability
1610
4 cells were plated into each well of a 96-well plate and
treated with the various concentrations of drugs for different
indicated times. At the end of each time point, 100 ml of MTT
solution (0.5 mg/ml) was added to each well. Cells were then
incubated at 37uC for 1 h. The MTT crystals in each well were
solubilized with 100 ml of DMSO. Absorbance was read at
550 nm.
Western blot assay
Following exposure to various drugs, cancer cells were washed
with PBS and lysed for 10 min at 4uC in a lysis buffer (50 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton X-100, 20 mg/ml leupeptin, 2 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride, 5 mM sodium fluoride, and
5,000 units/ml aprotinin). Equal proteins were separated by SDS-
Figure 1. Chemical structures of the withanolide compounds.
doi:10.1371/journal.pone.0037764.g001
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visualization using the enhanced chemiluminescence (ECL)
reagent (Amersham Pharmacia Biotech). For analysis of disul-
fide-linked Hsp90 by non-reducing SDS-PAGE, drug-treated cells
were washed with PBS at the indicated periods and then incubated
with iodoacetamide (40 mM) for 5 min to prevent thiol-disulfide
exchange and post-lysis oxidation of free cysteines [9]. Moreover,
samples were diluted in SDS-sample buffer without reducing
agents before loading onto SDS-polyacrylamide gels.
Annexin V/propridium iodide (PI) staining
Annexin V/PI staining was performed as previously described
[10]. Cancer cells (2610
5 cells) were seeded onto each well of a 6-
well plate and treated with DMSO or test drugs for 48 h. Treated
cells were harvested by trypsinization and stained with annexin V
and PI for 15 min at room temperature in the dark according to
the manufacturer’s instructions (BD Pharmingen). Apoptotic cells
were quantified by flow cytometry (Beckman Coulter, EPICS XL-
MCL). Stained cell populations were defined as: lower left
quadrant, living cells (annexin V
2/PI
2); lower right quadrant,
early apoptotic cells (annexin V
+/PI
2); upper right quadrant, late
apoptotic cells (annexin V
+/PI
+); upper left quadrant, primary
necrotic cells (annexin V
2/PI
+).
In vivo Hsp90 chaperone activity assay
The measurement of Hsp90 chaperone activity in intact cells
was carried out by the methods of Schneider et al. [11] and
Herna ´ndez et al. [12] with slight modifications. MDA-MB-231
cells were transfected with a pGL2-sv40-luciferase plasmid. The
luciferase-expressed cells were treated with DMSO or test drugs at
37uC for 30 min, and then transferred to 42uC for another
15 min. After heat shock treatment, the cells were left to recover at
37uC for 10 or 60 min. Subsequently, luciferase activity in the cells
was determined by One-Glo
TM luciferase assay (Promega,
Madison, WI) according to the manufacturer’s protocol.
Figure 2. Effect of the withanolides on the viability of MDA-MB-231 cells. (A) MDA-MB-231 cells were treated with the indicated
concentrations of various withanolide compounds for 48 h, and cell viability was determined by the MTT assay. (B) The IC50 values of the withanolides
on the viability of MDA-MB-231 cells. Results are presented as means 6 S.E.M. (n=3).
doi:10.1371/journal.pone.0037764.g002
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shRNA plasmid against Hsp70 (clone TRCN0000005945) or
control plasmid (clone TRCN0000072223) were obtained from
the National RNAi Core Facility located at the Institute of
Molecular Biology/Genomic Research Center, Academia Sinica,
Taiwan. To knockdown Hsp70 expression in MDA-MB-231 cells,
shRNA plasmid against Hsp70 or control plasmid was introduced
into the cells using Lipofectamine 2000 (Invitrogen) according to
Figure 3. Withanolides induce apoptosis in MDA-MB-231 cells. (A) Cells were treated with the indicated concentrations of WA, HW, AA, and
geldanamycin (GM) for 48 h. After treatment, cells were harvested and analyzed for PARP and caspase-3 by Western blot. (B) Cells were treated with
WA (5 mM), HW (20 mM), AA (20 mM), or GM (10 mM) for 48 h. Harvested cells were then stained with annexin V-FITC and PI and analyzed by flow
cytometry. Percentages of annexin V-positive cells were calculated by combining annexin V
+/PI
2 (lower right quadrants) and annexin V
+/PI
+ (upper
right quadrants) cells. Results are presented as means 6 S.E.M. (n=3).
doi:10.1371/journal.pone.0037764.g003
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tion, the cells were treated with the withanolides.
Statistics
Data are presented as means 6 S.E.M., and comparisons were
made using Student’s t test or one-way ANOVA. A probability of
0.05 or less was considered statistically significant.
Results
Structure-cytotoxicity relationships of withanolides in
MDA-MB-231 cells
Nine withanolides, including withaferin A (WA), tubocapseno-
lide A (TA), 4b-hydroxywithanolide (HW), withanolide E (WE),
tubocapsanolide E (TE), anomanolide A (AA), tubocapsenolide B
(TB), tubocapsanolide C (TC), and peruvianolide H (PH) (Fig. 1),
were tested in the human breast cancer MDA-MB-231 cells for
their cytotoxicity using the MTT assay. Fig. 2 shows that these
withanolides reduced cell viability with different potency. The
analysis of the structure-cytotoxicity relationships reveals that the
a, b-unsaturated ketone in ring A is essential for the cytotoxicity of
withanolides, since TB, TC, and PH, which lack the 2,3-
unsaturated double bond, lost cytotoxic activity in MDA-MB-
231 cells. Among the 2,3-unsaturated double bond-containing
withanolides, WA and TA are the most potent cytotoxic
compounds, and both have an additional 4b-hydroxy group and
a5 b,6b-epoxide. In contrast, compounds lacking the 4b-hydroxy
group (i.e., WE) or the 5b,6b-epoxide (i.e., TE) significantly
reduced their cytotoxicity. These results suggest either or both of
the two substitutions can enhance the cytotoxicity of withanolides.
On the other hand, the addition of a hydroxyl group to C20 (i.e.,
HW and WE) reduces the cytotoxic effect of withanolides.
Withanolides induce apoptosis in MDA-MB-231 cells
WA, HW, AA, and PH were chosen for the further studies
based on their different chemical characteristics and cytotoxicity.
Figure 4. Withanolides induce degradation of Hsp90 client proteins and induction of Hsp70 in MDA-MB-231 cells. (A) Cells were
treated with the indicated concentrations of various withanolide compounds for 12 h. After treatment, cells were harvested and analyzed for the
Hsp90 client proteins (Raf-1, CDK4, and Akt), a non-Hsp90 client protein p85, and Hsp70 by Western blot. (B) Concentration-dependent effect of WA,
HW, and AA on the Hsp90 client proteins and Hsp70. GM (10 mM) was used as a positive control. (C, D) Knockdown of Hsp70 enhances the pro-
apoptotic effect of the withanolides. MDA-MB-231 cells were transfected with shRNA plasmid against Hsp70 or control plasmid for 48 h. The
knockdown efficiency of shRNA for Hsp70 was confirmed by Western blot (C). The transfected cells were treated with WA (2 mM), HW (5 mM), or AA
(20 mM) for another 48 h for determining apoptosis (D).
doi:10.1371/journal.pone.0037764.g004
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was also studied in parallel with the withanolides. We investigated
if the withanolides induce apoptotic death in MDA-MB-231 cells.
The activation of caspase-3, which is an important effector
caspase, has been used as a indicator of apoptosis and, this process
can be determined by a decrease in pro-enzyme levels using
Western blot analysis. Figure 3a showed that the protein levels of
procaspase-3 were decreased in MDA-MB-231 cells after treat-
ment of WA (5 mM), HW (20 mM), AA (20 mM), or GM (10 mM)
for 48 h. The activation of caspase-3 by the withanolides and GM
was further confirmed by detecting the degradation of PARP,
which is a DNA repair enzyme and undergo cleavage by caspase-3
during apoptosis. In contrast to other withanolides, PH induced
neither caspase-3 activation nor PARP cleavage.
In order to quantify withanolide-induced apoptosis, we also
performed flow cytometric analysis using annexin V-FITC/PI
double staining. Annexin V has been widely used to detect the
exposed phosphatidylserine on cell surface during apoptosis. When
combined with PI, which stains cells that have lost membrane
integrity, this approach allows a further distinction of early
apoptotic (annexin V
+/PI
2), late apoptotic/necrotic (annexin V
+/
PI
+) cells, and primary necrotic cells (annexin V
2/PI
+). Figure 3b
shows that treatment of MDA-MB-231 cells with WA (5 mM), HW
(20 mM), AA (20 mM), or GM (10 mM) for 48 h led to significant
increases of both early and late apoptotic cells.
Withanolides induce degradation of Hsp90 client
proteins and induction of Hsp70
We next determined the effect of withanolides on protein levels
of the Hsp90 client proteins Akt, Raf-1, and CDK4 in MDA-MB-
231 cells. As shown in Fig. 4A and B, at the concentration of
5 mM, both WA and TA treatments markedly reduced Akt, Raf-1,
and CDK4 levels. At a higher concentration (20 mM), HW, WE,
TE, and AA also caused significant decreases in Raf-1 and CDK4
levels and, to a less extent, Akt levels. The effect of the
withanolides on Hsp90 client proteins was accompanied by an
increase in Hsp70 expression. In contrast, the non-Hsp90 client
protein PI3K p85 subunit was not affected. Importantly, TB, TC,
and PH, which are weakly cytotoxic withanolides, did not reduce
the amounts of the Hsp90 client proteins and did not induce
Hsp70 expression in cancer cells.
Hsp70 is known as an anti-apoptotic protein, and previous
studies have shown that induction of Hsp70 following Hsp90
inhibition attenuates the cytotoxic effect of Hsp90 inhibitors
[13,14]. In order to determine the role of Hsp70 induction on
withanolide-induced apoptosis, we used shRNA to reduce Hsp70
levels in MDA-MB-231 cells. The capacity of the shRNA against
Hsp70 was confirmed using Western blot (Fig. 4 C). As shown in
Fig. 4D, Hsp70 knockdown enhanced the pro-apoptotic effect of
WA, HW, and AA. This result suggests that like other Hsp90
inhibitors, up-regulation of Hsp70 also plays a protective
mechanism against withanolide-induced apoptosis.
Figure 5. Effect of heat shock on luciferase expressed in vivo in the presence of withanolides. MDA-MB-231 cells expressed luciferase
were pretreated DMSO or withanolides in 96-well plates for 30 min before incubation at 42uC for 15 min. After heat shock treatment, cells were left to
recover at 37uC for 10 or 60 min. Luciferase activity was assayed on whole-cell lysates. Results are presented as means 6 S.E.M. (n=3). *P,0.05,
**P,0.01, **P,0.001 as compared with the no heat shock group.
#P,0.05,
##P,0.01,
###P,0.001 as compared with the DMSO group which was
recovered for 60 min after heat shock.
doi:10.1371/journal.pone.0037764.g005
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In order to investigate if withanolides-induced degradations of
Akt, Raf-1, and CDK4 were due to inhibition of the chaperone
activity of Hsp90, an in vivo heat shock luciferase activity recovery
assay was used. It has been reported that firefly luciferase
expressed in mammalian cells denatures at high temperatures
but refolds upon temperature downshift in an Hsp90-dependent
manner [11]. In the present study, 293T cells transfected with
firefly luciferase-expressing plasmid was heat-stressed at 42uC for
15 min. The cells were then shifted to 37uC for 10 min and
60 min to recover the luciferase activity. As shown in Fig. 5, after
10 min and 60 min recovery, the luciferase activity reaching 69%
and 86% of control activity, respectively. In the presence of
geldanamycin (10 mM), luciferase activity was only 49% of control
levels after 60 min recovery at 37uC, indicating that Hsp90
involves in the refolding processes. Similar to geldanamycin, WA
(1–5 mM), HW (5–20 mM), and AA (5–20 mM) inhibited luciferase
refolding in a concentration-dependent manner. In contrast, PH
did not affect the recovery of luciferase activity.
Withanolides-induced cell death and Hsp90 inhibition
are prevented by N-acetylcysteine
In the previous studies, TA and WA have been reported to
induce thiol oxidation and aggregation of Hsp90 by promoting the
formation of intermolecular disulfide bonds [5,6]. In the present
work, we found that when MDA-MB-231 cells were treated with
WA, TA, HW or AA, disulfide-linked Hsp90 with higher
molecular weight appeared in both the Triton-soluble fraction
and the Triton-insoluble fraction, and migrated slower than the
native Hsp90 in non-reducing SDS-PAGE (Fig. 6A). These results
suggested that Hsp90 was oxidative-damaged and formed
insoluble aggregates in cancer cells treated with the withanolides.
In contrast, the less-cytotoxic withanolide PH, had no effect on the
oxidation and aggregation of Hsp90.
We next used an antioxidant N-acetylcysteine (NAC), which
contains a reduced sulfhydryl group, to prevent the oxidation of
Hsp90. In the presence of NAC, the effects of WA, HW, and AA
on Hsp90 client proteins and Hsp70 induction were abolished
(Fig. 6B). Furthermore, cell death induced by these withanolides
was also markedly prevented (Fig. 6C).
Effect of withanolides and geldanamycin on IKK and NF-
kB
IkB kinase (IKK), a key regulator in the NF-kB pathway, has
been reported to be a Hsp90 client protein [15]. In addition, the
NF-kB pathway is constitutively active in estrogen receptor (ER)-
negative breast cancer cells and contributes to their hormone-
independent growth [16]. Therefore, we wanted to investigate the
effect of withanolides on IKK and NF-kB. Fig. 7A shows that
treatment of MDA-MB-231 cells with WA, HW or AA led to a
decrease in both IKKa and IKKb. The rank order of potency was
WA.HW.AA. Geldanamycin treatment also induced IKK
depletion. Withanolides- and geldanamycin- induced IKK deple-
tion was accompanied by IkB de-phosphorylation and IkB
accumulation and, resulted in inhibition of NF-kB activation as
evidenced by the decrease in Ser536 phosphorylation. The
Figure 6. Withanolides cause thiol oxidation and aggregation of Hsp90 in MDA-MB-231 cells. (A) Cells were treated with WA (5 mM), TA
(5 mM), HW (20 mM), AA (20 mM) or PH (20 mM) for 12 h. The Triton-insoluble fractions of cell lysates were prepared as described under ‘‘Experimental
Procedures.’’ The protein levels of the disulfide-linked-Hsp 90 were analyzed by nonreducing SDS-PAGE. (B, C) The thiol-reducing agent NAC prevents
the degradation of Hsp90 client proteins and cell death caused by withanolides. MDA-MB-231 cells were pretreated with or without NAC (2.5 mM) for
1 h before challenged with withanolides for 12 h (B) or 48 h (C). The protein levels of heat shock proteins and client proteins were analyzed by
western blot (B). The viability of MDA-MB-231 cells was determined by the MTT assay (C). Results are presented as means 6 S.E.M. (n=3). **P,0.01,
***P,0.001 as compared with each group without NAC pretreated.
doi:10.1371/journal.pone.0037764.g006
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supported by that NF-kB-regulated gene products Bcl-2, Bcl-xL,
and c-FLIP [17,18] were reduced by WA, HW, and AA. PH,
which was inactive in inhibiting Hsp90, did not affect IKK levels
and failed to inhibit NF-kB activation (Fig. 7B).
In addition, NAC pretreatment completely prevented the effect
of withanolides on IKK and NF-kB. In contrast, NAC only
partially reversed the effect of geldanamycin (Fig. 7C).
Effect of the withanolides on ER-positive human breast
cancer cells
In order to confirm the generality of the Hsp90-inhibitory effect
of the withanolides, another human breast cancer cell line MCF-7,
which expresses ER, was treated with the compounds. As shown in
Fig. 8A, the withanolides reduced the viability of MCF-7 cells,
with potency in the order WA.HW.AA.PH. WA and HW also
induced apoptotic death in MCF-7 cells as evidenced by a
decrease of procaspase-7 and the cleavage of PARP (Fig. 8B).
Furthermore, in correlation with their cytotoxicity, the with-
anolides reduced the levels of Hsp90-client proteins (Akt and Raf-
1) and induced Hsp70 overexpression in MCF-7 cells (Fig. 8C). In
addition, the withanolides reduced the expression of ER in MCF-7
cells (Fig. 8C), but the rank order of potency was HW§WA.-
PH.AA.
As observed in MDA-MB-231 cells, the treatment of MCF-7
cells with the withanolides also resulted in a decrease in the levels
of both IKKa and IKKb, with the consequent decrease in the
phosphorylation of IkB and NF-kB (Fig. 8D).
Discussion
There are several mechanisms of action proposed for with-
anolides, including NF-kB inhibition, PAR-4 induction, actin
microfilament and/or vimentin intermediate filament aggregation,
ROS formation, proteasome inhibition and Hsp90 inhibition
[5,19–24]; however, it remains unclear which of them is a
common property and contributes mainly to the anticancer
activities of withanolides. In this work, we found that a panel of
withanolides inhibited Hsp90 function in human breast cancer
cells, as measured by depletion of client proteins and by chaperone
activity, to different extents. Furthermore, there is a good
correlation between Hsp90 inhibition and the cytotoxic effect
caused by the withanolides. These results support that Hsp90
inhibition is an important mechanism of anticancer activity of
withanolides.
The Hsp90-inhibitory effect of withanolides was apparent due
to induction of oxidative insults of Hsp90 as shown in the previous
reports [5,6], because withanolides that inhibited Hsp90 functions
also induced Hsp90 oxidation and aggregation, and the thiol
antioxidant NAC prevented both oxidative insults and function
loss of Hsp90 caused by the withanolides. Structure-activity
analysis of the withanolides in the present study indicates that the
a, b-unsaturated ketone in ring A is critical for inducing Hsp90
oxidative damage. a, b-Unsaturated ketones are strong electro-
philics which can react with protein cysteine residues by Michael
addition that results in thiol alkylation and/or thiol oxidation [25].
Besides the a, b-unsaturated ketone, the epoxide in ring B and the
conjugated ketone in the lactone ring of withanolides are also
electrophilic moieties [26]. However, the electrophilicity of the
conjugated ketone in the lactone ring is much lower than that of a,
b-unsaturated ketone, since a methyl substitution at the b-position
of the former prevents nucleophilic attack. As a result, the
withanolides containing only a conjugated ketone in the lactone
ring (eg. PH) had no or little effect on Hsp90 oxidation and
inhibition.
Several withanolides, including WA, have been reported to
inhibit NF-kB activation in tumor necrosis factor (TNF)-stimulat-
ed cells [19,27,28]. Although the mechanisms involved in NF-kB
inhibition by withanolides are not fully understood, previous
studies have shown that withanolides can inhibit IkB phosphor-
ylation and degradation with consequent reduction of NF-kBi n
the nucleus [27]. The IkB kinase complex contains two kinase
subunits, IKKa and IKKb is the upstream kinase responsible for
IkB phosphorylation, which leads to proteasome-dependent
degradation of IkB. Both IKKa and IKKb have been suggested
as Hsp90 client proteins, since Hsp90 inhibition leads to the
degradation of IKKs [15,29,30]. In the present study, we show for
the first time that withanolides caused both IKKa and IKKb
depletion in human breast cancer cells; moreover, this effect was
correlated with their Hsp90-inhibitory activities. The depletion of
IKKs by withanolides was accompanied with reduced both
phosphorylation and degradation of IkB, and led to inhibition of
NF-kB activation, indicating that withanolides inhibit the NF-kB
pathway by targeting IKKs.
NF-kB is constitutively active in most types of cancer and plays
an important role in the development and progression, and
Figure 7. Effect of withanolide on the IKK/NF-kB pathway. (A)
Withanolides induce IKK degradation and inhibit NF-kB activation.
MDA-MB-231 cells were treated with WA (5 mM), HW (20 mM), AA
(20 mM), PH (20 mM) or GM (10 mM) for 12 h. After treatment, cells were
harvested and analyzed for the proteins involved in the NF-kB pathway
by Western blotting. (B) Withanolides decrease anti-apoptotic proteins
that are regulated by NF-kB. Cells were treated with withanolides for
48 h. After treatment, cells were harvested and analyzed for Bcl-2, Bcl-
xL, and c-FLIP by Western blotting. (C) NAC prevents IKK degradation
and NF-kB inhibition by WA. Cells were treated with WA (5 mM) or GM
(10 mM) in the absence or presence of NAC (2.5 mM) for 12 h. After
treatment, cells were harvested and subjected to Western blotting.
doi:10.1371/journal.pone.0037764.g007
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radiotherapy [31,32]. In human breast cancer cell lines or
specimens, the NF-kB signaling is inversely related to estrogen
receptor (ER) expression [16,33]. The constitutive activation of
NF-kB promotes the more invasive phenotype of ER-negative
cancer cells via induction of anti-apoptotic and pro-metastatic
genes, such as Bcl-2 and granulocyte macrophage-colony
stimulating factor (GM-CSF) [34,35]. Moreover, the inhibition
of NF-kB signaling induces apoptosis in ER-negative breast
cancer cells [36,37]. These findings suggest that NF-kBi sa
potential target for the treatment of metastatic estrogen-
independent breast cancer. In the present study, we show that
withanolides inhibited the constitutive activation of NF-kBi n
MDA-MB-231, an ER-negative human breast cancer cell line,
and reduced the anti-apoptotic proteins (Bcl-2, Bcl-xL, and c-
FLIP) which are regulated by NF-kB. Given the importance of
NF-kB in cancer cell survival, it is suggested that the inhibition of
the IKK/NF-kB pathway may contribute to the anticancer effect
of withanolides.
In contrast to MDA-MB-231 cells, the survival of ER-positive
breast cancer cells, such as MCF-7, are less dependent on the
IKK/NF-kB pathway [37]. Therefore, the inhibition of IKK/
NF-kB by withanolides may not play a major role in their
cytotoxicity against MCF-7. On the other hand, the withanolides
exhibits potent inhibition of ER expression, an effect potentially
lined to suppression of ER-dependent proliferation of breast
cancer cells [38]. The reduced ER expression by withanolides
may be, at least in part, due to inhibition of Hsp90, since ER is
also a Hsp90 client protein [39,40]. Of note, HW exhibits greater
inhibitory effect on ER expression than that of WA suggesting
that mechanisms other than Hsp90 inhibition may also contrib-
ute to its action on ER.
In conclusion, structure-activity analysis of a panel of with-
anolides reveals that 2,3-unsaturated double bond-containing
withanolides exhibit potent inhibitory effect on Hsp90 chaperone
activity. The inhibition of Hsp90 by the withanolides causes the
depletion of several important signaling molecules involved in cell
survival, including IKKs, and thus contributes to the anticancer
effect of the withanolides.
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Figure 8. Effect of the withanolides on ER-positive human breast cancer cells. (A) Withanolides reduce the viability of MCF-7 cells. MCF-7
cells were treated with the indicated concentrations of WA, HW, AA, or PH for 48 h, and cell viability was determined by the MTT assay. (B)
Withanolides induce caspase-7 activation and PARP cleavage. MCF-7 cells were treated with the withanolides for 48 h. After treatment, cells were
harvested and analyzed for caspase-7 and PARP by Western blot. (C) Withanolides induce degradation of Hsp90 client proteins and induction of
Hsp70. MCF-7 cells were treated with the withanolides or GM for 12 h. Levels of Hsp90 client proteins and Hsp70 were determined by Western blot.
(D) Withanolides induce IKK degradation and inhibit NF-kB activation. MCF-7 cells were treated with the withanolides or GM for 12 h. After treatment,
cells were harvested and analyzed for the proteins involved in the NF-kB pathway by Western blot.
doi:10.1371/journal.pone.0037764.g008
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